ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

19.95 +0.06 (+0.30%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Why Is Acadia Pharmaceuticals (ACAD) Stock Down 18% Today? ↗

March 12, 2024

Acadia Pharmaceuticals stock is falling on Tuesday as investors in ACAD react to its failed Phase 3 clinical trial of pimavanserin.

Via InvestorPlace

Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

March 12, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Acadia Hits 11-Month Low After Outsized Placebo Effect Torpedoes Schizophrenia Study ↗

March 12, 2024

The company says it doesn't plan to further develop Nuplazid in clinical testing.

Via Investor's Business Daily

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 12, 2024

Via Benzinga

Why Oracle Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗

March 12, 2024

Shares of Oracle Corporation (NYSE: ORCL) rose sharply in today’s pre-market trading after the company reported upbeat earnings for its fis

Via Benzinga

Beyond The Numbers: 13 Analysts Discuss ACADIA Pharmaceuticals Stock ↗

February 28, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

March 12, 2024

Pre-market stock movers are worth checking out this morning as we get into all of the biggest winners and losers for Tuesday!

Via InvestorPlace

Trial Setback For Acadia Pharmaceuticals' Late-Stage Schizophrenia Trial: Details ↗

March 12, 2024

Acadia Pharmaceuticals' Phase 3 ADVANCE-2 trial results on pimavanserin for schizophrenia-negative symptoms. Insights on efficacy, safety, and future considerations.

Via Benzinga

ACADIA Pharmaceuticals, Ocular Therapeutix, Asana And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

March 12, 2024

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining by around 50 points on Tuesday.

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

March 11, 2024

Via Benzinga

Recap: ACADIA Pharmaceuticals Q4 Earnings ↗

February 27, 2024

Via Benzinga

Earnings Scheduled For February 27, 2024 ↗

February 27, 2024

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.

Via Benzinga

Analyst Scoreboard: 12 Ratings For ACADIA Pharmaceuticals ↗

January 24, 2024

Via Benzinga

Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia

March 11, 2024

From Acadia Pharmaceuticals Inc.

Via Business Wire

3 Stock Winners That Are Up 1,000% or More in 2024 ↗

March 08, 2024

Dig deep enough, and find a story hot enough, and you can uncover potential stock winners up 1,000%. Here are three.

Via InvestorPlace

Acadia Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference on March 6, 2024

February 29, 2024

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Stock Dives As Unexpected Seasonality Rocks Its Most High-Profile Launch ↗

February 28, 2024

CEO Steve Davis said there was a lot of pent-up demand when Daybue first launched last year.

Via Investor's Business Daily

Deep Dive Into ACADIA Pharmaceuticals Stock: Analyst Perspectives (13 Ratings) ↗

December 29, 2023

Via Benzinga

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview

February 27, 2024

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 21, 2024

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

February 13, 2024

From Acadia Pharmaceuticals Inc.

Via Business Wire

The 3 Most Undervalued Biotech Stocks to Buy in February 2024 ↗

February 08, 2024

With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider.

Via InvestorPlace

Acadia Announces Additions to Executive Team

January 30, 2024

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 19, 2024

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Announces the Passing of Former President Srdjan (Serge) Stankovic

January 18, 2024

From Acadia Pharmaceuticals Inc.

Via Business Wire

Expedia To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Friday ↗

December 29, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Acadia Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024

December 21, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 18, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Delaware District Court Rules in Favor of Acadia on Formulation Patent Construction (Markman) Claims Regarding NUPLAZID® (pimavanserin)

December 13, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Soars To A Four-Month High After Winning A Patent Battle For Its Biggest Drug ↗

December 13, 2023

MSN Labs lost out in a summary judgement to knock off Acadia's Nuplazid.

Via Investor's Business Daily

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.